PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Baljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.

Make the most of your practice and your retina conference participation.

Innovative assistive devices empower patients with central vision loss to regain independence and enhance daily activities, transforming their quality of life.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Catch up on this week's highlights in retina.

The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease.

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD).

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.

Ocular Therapeutix showcases innovative TKI treatments for retinal diseases at the Clinical Trials Summit in Las Vegas, June 21, 2025.

Looking at innovative tools and their applications in different disease states can help to think creatively about ways to benefit patients in retina care.

Ainnova has collaborated with leading pharmacies to offer free diabetic retinopathy screenings to patients with diabetes.

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

Investigators take an in-depth look at all aspects of the technology.

A mutation-agnostic gene therapy approach offers new possibilities for patients with advanced retinal disease.

The report highlights clinical successes, innovation, research, and patient outcomes.

Catch up on this week's highlights in retina.

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery.